Study of ovarian cancer management

• Published in: Irish medical journal 2006-10, Vol.99 (9), p.279-280
• Main Authors: Gaughan, E, Javaid, T, Cooley, S, Byrne, P, Gaughan, G
• Format: Article
• Language: English
• Subjects: Adult; Cystadenocarcinoma, Papillary - diagnosis; Cystadenocarcinoma, Papillary - mortality; Cystadenocarcinoma, Papillary - pathology; Cystadenocarcinoma, Papillary - surgery; Cystadenocarcinoma, Serous - diagnosis; Cystadenocarcinoma, Serous - mortality; Cystadenocarcinoma, Serous - pathology; Cystadenocarcinoma, Serous - surgery; Female; Humans; Neoplasm Staging; Ovarian Neoplasms - diagnosis; Ovarian Neoplasms - mortality; Ovarian Neoplasms - pathology; Ovarian Neoplasms - surgery
• ISSN: 0332-3102

Ovarian cancer is the most lethal gynecological malignancy. Many patients present at an advanced stage as the symptoms of early stage disease can be vague. AIM We evaluated the demographics, treatment regimens and survival rates of ovarian cancer patients attending Beaumont Hospital Dublin over a nine year period. A retrospective chart review of ovarian cancer patients attending Beaumont Hospital between 11/10/94 and 30/6/3 was performed. Patients were selected from pathology records. Patients with borderline histology and those who died of unrelated causes were excluded. 31% of individuals presented with distension as their only clinical sign. 20% presented with a mass as their only clinical sign. The most common cell type was papillary serous adenocarcinoma in two thirds of cases. 54% presented with advanced disease [stage IIl-IV]. Treatment involved surgical clearance or debulking +/- chemotherapy. 5 year survival for Stage I was 95% versus 19% for Stage IlI. This highlights the importance of early diagnosis.